FLDM Fluidigm Corporation

Fluidigm Corporation (NASDAQ:FLDM) will unveil a new custom assay design service for high-sample throughput amplicon resequencing on Illumina platforms at this week’s Advances in Genome Biology and Technology (AGBT) meeting. The Access Array™ Target-Specific Primers, when used with the Fluidigm Access Array System, allow for fast, simple, and inexpensive preparation of up to 480 amplicons per sample at a time. This capability is ideal for analysis of large sample sets across focused genomic regions to better understand human genetic variation.

“Access Array Target-Specific Primers allow researchers to quickly and specifically amplify their target of interest, incorporate sample-specific barcodes and add sequencer-specific adaptors – all at the same time. This by-passes library preparation altogether,” said Gajus Worthington, Fluidigm President and CEO.

“With our new Access Array Target-Specific Primers, we increase the number of amplicons per sample by 10X compared to our traditional solution. In conjunction with our Access Array Barcode Library for Illumina Sequencers, up to 384 unique samples can be multiplexed per sequencing run. This will help scientists capture the maximum output of their sequencers and provide the broadest coverage possible for their human genetic variation studies,” Worthington concluded.

The Fluidigm Access Array System prepares amplicons for resequencing without the need for any additional library preparation and can operate with any next-generation sequencer (NGS) on the market. It prepares these amplicons in just hours, instead of days, and performs the sample preparation for less than $10 per sample. In addition, using the Access Array Barcode Libraries developed for the Illumina, Roche, and Ion Torrent sequencing platforms, researchers can test the same amplicon pools to cross-validate sequencing results across different NGS platforms.

Use of Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements relating to our new products/services and our plans, objectives, expectations and/or strategies relating to such new products and services. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results. Factors that could materially affect future results include, but are not limited to, challenges inherent in developing, manufacturing, and launching new products and services and the other risk factors contained in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q. These forward-looking statements speak only as of the date hereof. Fluidigm Corporation disclaims any obligation to update these forward-looking statements.

About Fluidigm

Fluidigm (NASDAQ:FLDM) develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio, industries. Fluidigm’s proprietary microfluidic systems consist of instruments and consumables, including chips, assays and other reagents. These systems are designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm actively markets three microfluidic systems, including eight different commercial chips, to leading pharmaceutical and biotechnology companies, academic institutions and Ag-Bio companies.

For more information, please visit www.fluidigm.com.

Fluidigm, the Fluidigm logo, Access Array are trademarks or registered trademarks of Fluidigm Corporation.

Fluidigm (NASDAQ:FLDM)
過去 株価チャート
から 6 2026 まで 7 2026

Fluidigm (NASDAQ:FLDM)
過去 株価チャート
から 7 2025 まで 7 2026